At-home diagnostic services provider Getlabs has announced the addition of Grail‘s Galleri multi-cancer early detection test into its suite of offerings.
This move is set to transform the landscape of cancer screening by providing a convenient at-home blood draw option for the Galleri test.
Go deeper with GlobalData
The test works by analysing cell-free DNA (cfDNA) fragments in the blood to screen for various cancers, including those without current screening recommendations such as pancreatic, esophageal, ovarian, and liver cancers.
In contrast to the existing screening methods that target individual cancer types, the Galleri test has the potential to detect many of the deadliest cancers early.
The current US screening paradigm only covers five types of cancer: breast, colon, cervical, prostate, and lung cancer in high-risk adults. This approach does not significantly reduce cancer-related mortality as it overlooks the majority of cancer types.
By partnering with Grail, Getlabs aims to make early cancer detection more widely accessible.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThis is particularly beneficial for individuals who have limited access to healthcare facilities or face logistical challenges in visiting clinics.
Getlabs CEO Kyle Michelson said: “Partnering with GRAIL allows us to extend the reach of early cancer detection and make it even more convenient for patients to prioritise their health.
“By leveraging our expertise in at-home diagnostic collections, we can greatly expand access to critical cancer screening services. Our partnership with GRAIL represents a step forward in saving lives through early cancer detection.”
Last year, Illumina announced its intention to challenge the European Commission’s (EC) ruling calling for the company to divest itself of its newly acquired Grail.
